Related references
Note: Only part of the references are listed.T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis
Keiji Hirota et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Treatment of rheumatoid arthritis
Angelo Gaffo et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis
M. I. Koenders et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
H Mitoma et al.
GASTROENTEROLOGY (2005)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist
S Nakae et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tumor necrosis factor-α blockade:: A novel therapy for rheumatic disease
JC Shanahan et al.
CLINICAL IMMUNOLOGY (2002)
Anti-interleukin-1 therapy in rheumatic diseases
JM Dayer et al.
CURRENT OPINION IN RHEUMATOLOGY (2001)